|
1. |
What is Known About AutismGenes, Brain, and Behavior |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 71-92
Susan L Santangelo,
Katherine Tsatsanis,
Preview
|
PDF (300KB)
|
|
摘要:
Autism is a neurodevelopmental disorder of genetic origins, with a heritability of about 90%. Autistic disorder is classed within the broad domain of pervasive developmental disorders (PDD) that also includes Rett syndrome, childhood disintegrative disorder, Asperger syndrome, and PDD not otherwise specified (PDD-NOS). Prevalence estimates suggest a rate of 0.1–0.2% for autism and 0.6% for the range of PDD disorders. There is considerable phenotypic heterogeneity within this class of disorders as well as continued debate regarding their clinical boundaries. Autism is the prototypical PDD, and is characterized by impairments in three core domains: social interaction, language development, and patterns of behavior (restricted and stereotyped). Clinical pattern and severity of impairment vary along these dimensions, and the level of cognitive functioning of individuals with autism spans the entire range, from profound mental retardation to superior intellect.There is no single biological or clinical marker for autism, nor is it expected that a single gene is responsible for its expression; as many as 15+ genes may be involved. However, environmental influences are also important, as concordance in monozygotic twins is less than 100% and the phenotypic expression of the disorder varies widely, even within monozygotic twins. Multiple susceptibility factors are being explored using varied methodologies, including genome-wide linkage studies, and family- and case-control candidate gene association studies. This paper reviews what is currently known about the genetic and environmental risk factors, neuropathology, and psychopharmacology of autism. Discussion of genetic factors focuses on the findings from linkage and association studies, the results of which have implicated the involvement of nearly every chromosome in the human genome. However, the most consistently replicated linkage findings have been on chromosome 7q, 2q, and 15q. The positive associations from candidate gene studies are largely unreplicated, with the possible exceptions of theGABRB3and serotonin transporter genes.No single region of the brain or pathophysiological mechanism has yet been identified as being associated with autism. Postmortem findings, animal models, and neuroimaging studies have focused on the cerebellum, frontal cortex, hippocampus, and especially the amygdala. The cerebello-thalamo-cortical circuit may also be influential in autism. There is evidence that overall brain size is increased in some individuals with autism.Presently there are no drugs that produce major improvements in the core social or pragmatic language deficits in autism, although several have limited effects on associated behavioral features.The application of new techniques in autism research is being proposed, including the investigation of abnormal regulation of gene expression, proteomics, and the use of MRI and postmortem analysis of the brain.
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
2. |
Platelet Glycoprotein IIb/IIIa Polymorphism and Coronary Artery DiseaseImplications for Clinical Practice |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 93-99
Augusto Di Castelnuovo,
Giovanni de Gaetano,
Maria Benedetta Donati,
Licia Iacoviello,
Preview
|
PDF (204KB)
|
|
摘要:
Membrane glycoprotein (GP) IIb/IIIa plays a major role in platelet function; indeed it enables stimulated platelets to bind fibrinogen and related adhesive proteins, a process that is considered key in the development of thrombosis. The gene encoding GPIIIa (ITGB3, also known asGP3A) shows a common platelet antigen polymorphism [PL(A1)/PL(A2); expressed by allelesITGB3*001 andITGB3*002] that was variably associated with vascular disease. In 1996, the presence of the PL(A2) allele (ITGB3*001) was first reported to increase the risk of coronary heart disease. Shortly after, the interest in this study was increased by the publication of a case report on the death from myocardial infarction of an Olympic athlete who was found to be homozygous for the PL(A2) allele. Overviews of the published studies on the PL(A1)/PL(A2) polymorphism and coronary risk suggest an influence of the PL(A2) allele on the clinical phenotype and the interaction with other environmental factors. In particular, the strongest effect of theITGB3PL(A2) allele was expressed on the risk of occlusion after revascularization procedures, mainly after stent implantation, a condition in which platelet activation is more important as compared with other stenotic mechanisms.In the future, the identification of patients who are particularly responsive to GPIIb/IIIa antagonist therapy (e.g. those with the PL(A2) allele) might help to improve the treatment efficacy in this relatively small population. In a mechanism possibly unrelated to its effect on platelet reactivity to aggregating stimuli, the presence of the PL(A2) allele might influence the antiaggregatory effect of platelet inhibitory drugs such as aspirin (acetylsalicylic acid), clopidogrel, and GPIIb/IIIa antagonists.Although interesting, current data does not yet have direct clinical implications for patient risk identification and drug therapy tailoring. Larger studies are necessary to define the role of the PL(A2) allele in more homogeneous groups where platelet GPIIb/IIIa activation might be particularly relevant.
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
3. |
Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 101-112
Heiko van der Kuip,
Lara Wohlbold,
Carsten Oetzel,
Matthias Schwab,
Walter E Aulitzky,
Preview
|
PDF (243KB)
|
|
摘要:
A number of highly specific small molecule inhibitors of oncogenic tyrosine kinases have been developed and may potentially improve the treatment of different malignant diseases. However, it became rapidly evident that multiple resistance mechanisms compromise the successful clinical application of these inhibitors, particularly in advanced solid tumors.To develop efficient therapeutic strategies with small molecule inhibitors, one must understand the causes for treatment failure. Three different types of resistance to small molecule inhibitors of oncogenic tyrosine kinases have been observed. The malignant phenotype may be independent of the activity of the target kinase (target-independent resistance). Alternatively, overexpression or mutation of the target kinase can counteract the inhibition of oncogenic tyrosine kinases (target-dependent resistance). Finally, alterations of drug transporters or drug-metabolizing pathways may block the bioavailability of the tyrosine kinase inhibitors (drug-dependent resistance). This article reviews the current knowledge of clinical resistance to small molecule inhibitors approved for treatment of cancer patients.
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
4. |
Pathway ProteomicsGlobal and Focused Approaches |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 113-122
György Marko-Varga,
Preview
|
PDF (339KB)
|
|
摘要:
Biological pathways represent the relationships (reactions and interactions) between biological molecules in the context of normal cellular functions and disease mechanisms. Understanding the roles of proteins and signaling pathways expressed within disease, and their link to drug discovery and drug development are central in today’s target-driven pharmaceutical processes.This article gives an overview of proteomics strategies, including global expression analysis as well as focused approaches using multidimensional separation by both gel- and liquid-phase techniques linked to mass spectrometry, as applied to two of the pathways involved in inflammatory diseases. In primary human cell studies, our group has annotated and identified thousands of proteins using both electrospray ionization and matrix-assisted laser desorption ionization (MALDI)-sequencing technology. Annotations made from gel images and chromatography fractionation, interfaced to high-end mass spectrometry sequence and structure identity, are cornerstones in cutting-edge protein expression profiling. Regarding phosphorylation mechanisms of kinases, the quantitative stoichiometry can be determined using affinity probe isolations. Another strategy involves micro-preparative sample processing, which has been used to analyze single-target phosphoproteins and their relative phospho-stoichiometry.
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
5. |
Detection of Single Nucleotide Polymorphisms in theABCG2Gene in a Dutch Population |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 123-131
Tessa M Bosch,
Linda M Kjellberg,
Anja Bouwers,
Bobby P C Koeleman,
Jan H M Schellens,
Jos H Beijnen,
Paul H M Smits,
Irma Meijerman,
Preview
|
PDF (282KB)
|
|
摘要:
BackgroundABCG2 is a drug transporter involved in the protection of tissues by actively transporting toxic substances and xenobiotics out of cells. Cancer cells overexpressing theABCG2gene show multidrug resistance to mitoxantrone-, methotrexate-, doxorubicin-, and camptothecin-based anticancer drugs, such as topotecan and SN-38. Large interindividual differences have been shown in oral availability and clearance of drugs that are substrates for ABCG2. Variation in theABCG2gene, such as single nucleotide polymorphisms (SNPs), can possibly explain the variability in pharmacokinetics of ABCG2 substrates.AimThis study was performed to screen for SNPs in theABCG2gene to determine the frequencies of currently known and previously unknown SNPs in a Dutch population.MethodsBlood samples were obtained from 100 healthy volunteers to isolate genomic DNA. PCR amplification was performed, followed by DNA sequencing. The population, of which the ethnicity was 93% Caucasian, consisted of 79 female individuals and 21 males.ResultsIn total, 19 SNPs were found in theABCG2gene, of which 7 were previously unknown. The SNPs G8883A in exon 5 and C44168T in exon 14 cause an amino acid change of R160Q and R575X, respectively. Most of the previously unknown SNPs were found in introns.ConclusionsThe results will be used in future studies to explore the influence of the different SNPs on ABCG2 protein expression, activity, and substrate specificity. In addition, the results can be used to study the effects of genetic polymorphisms in theABCG2gene on the pharmacokinetic profile of anticancer drugs.
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
6. |
Spotlight on Gefitinib in Non-Small-Cell Lung Cancer1 |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 133-136
James E Frampton,
Stephanie E Easthope,
Preview
|
PDF (182KB)
|
|
摘要:
Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). However, approved uses differ between countries; in most markets, gefitinib is approved for third-line use only (e.g. the US, Canada and Switzerland), although in some it is approved for both second- and third-line use (e.g. Japan and Australia) and, additionally, in patients considered unsuitable for chemotherapy (e.g. Indonesia and the Philippines).Few third-line treatment options exist for patients with inoperable advanced NSCLC who have failed both docetaxel and platinum-based chemotherapy regimens. Gefitinib represents a significant advance in the treatment of this population; a once-daily oral dosage of 250 mg/day was well tolerated, produced objective tumour responses and disease stabilization, and improved disease-related symptoms and quality of life. It also produced overall survival outcomes that compared favorably with historical outcomes in a similar group of patients treated with three or four different chemotherapy regimens. These findings have been supported by observations from a global compassionate-use program. Ongoing or planned clinical trials are designed to confirm and/or further define the role of the drug in the above and other clinical settings.Preliminary data demonstrate the presence of activating mutations in EGFR-TK among patients whose disease was highly responsive to treatment with gefitinib, although such mutations have not been correlated to all patients who benefit from the drug. Further studies are needed to fully elucidate the clinical implications ofEGFRmutations and to identify patients likely to benefit from EGFR-targeted therapy.
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
7. |
EGFR PharmacogenomicsThe Story Continues to Mutate and Evolve |
|
American Journal of PharmacoGenomics,
Volume 5,
Issue 2,
2005,
Page 137-139
Apurva A Desai,
Mark J Ratain,
Preview
|
PDF (147KB)
|
|
ISSN:1175-2203
出版商:ADIS
年代:2005
数据来源: ADIS
|
|